Gavin MacBeath - Feb 2, 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCRX	Stock Option (Right to Buy)	Award	$0	+40K		$0.00	40K	Feb 2, 2023	Voting Common Stock	40K	$1.81	Direct	F1

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.

Chief Scientific and Operations Officer